Back to Solutions
M&A and BD Advisory

M&A and BD Advisory

M&A target identification, due diligence, licensing deal strategy, and post-merger integration for pharmaceutical and life sciences companies.

100K+
Companies Screened
$50B+
Deal Value Supported
85%
Synergy Capture Rate
10x
Faster Diligence

Consulting Overview

Our M&A and BD Advisory service helps pharmaceutical and life sciences companies identify, evaluate, and execute strategic transactions that drive growth. From target identification to post-merger integration, we provide the intelligence and advisory support needed for successful deals.

Leveraging our AI-powered intelligence platform, we identify synergies, assess risks, and develop integration plans that maximize deal value and accelerate time-to-impact.

Strategic Service Areas

M&A Target Identification & Diligence

Target screening, valuation, commercial diligence, and synergy assessment for pharma M&A.

  • • Target screening and long-list development
  • • Commercial and scientific diligence
  • • Valuation and synergy assessment
  • • Risk evaluation and mitigation

Licensing & Partnership Strategy

Deal structuring, valuation, negotiation support, and partnership optimization.

  • • In-license and out-license strategy
  • • Deal valuation and term sheet development
  • • Negotiation support
  • • Partnership optimization

Post-Merger Integration

Integration planning, cultural alignment, synergy realization, and PMO support.

  • • Integration planning and roadmap
  • • Cultural alignment and change management
  • • Synergy tracking and realization
  • • PMO support and governance

Our Methodology

01

Discovery & Screening

Identify and screen potential targets using AI-powered intelligence and market analysis.

02

Diligence & Valuation

Comprehensive commercial, scientific, and financial diligence with valuation and synergy assessment.

03

Deal Execution

Negotiation support, deal structuring, and transaction execution with clear terms and protections.

04

Integration & Value Capture

Post-deal integration planning and execution to capture synergies and maximize value.

Key Capabilities

AI-Powered
Target Screening
Deep
Commercial Diligence
Robust
Valuation
End-to-End
PMI Support

Frequently Asked Questions

What types of M&A deals do you support?

We support the full spectrum of pharma M&A including acquisitions, mergers, divestments, in/out-licensing, joint ventures, and co-development deals across all therapeutic areas and geographies.

How does AI enhance your M&A advisory?

Our AI platform screens 100K+ companies, analyzes pipeline data across 400K+ clinical trials, evaluates patent landscapes, and assesses market dynamics to identify targets 10x faster than traditional methods.

Do you support post-merger integration?

Yes. We provide end-to-end PMI support including integration planning, cultural alignment, synergy tracking, PMO governance, and change management to ensure deal value is captured.

What is your typical engagement model?

We offer flexible engagement models from targeted diligence support to full deal advisory and PMI implementation, typically spanning 3-12 months depending on deal complexity.

Consulting Features

  • AI-powered target screening
  • Deep commercial diligence
  • Synergy quantification
  • Integration planning
  • Negotiation support
  • PMO and governance

Deal Types Supported

Mergers & Acquisitions
In/out-licensing
Joint ventures
Co-development
Divestments

Ready to Execute Your Next Deal?

Get expert M&A and BD advisory with AI-powered intelligence.

Schedule Consultation